Spero Therapeutics Stock Price

-0.18 (-8.7%)
Volume 3,197,977
Bid Price 1.85
Ask Price 1.89
News -
Day High 2.0797


52 Week Range


Day Low 1.82
Company Name Stock Ticker Symbol Market Type
Spero Therapeutics Inc SPRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.18 -8.7% 1.89 16:14:17
Open Price Low Price High Price Close Price Prev Close
2.05 1.82 2.0797 1.875 2.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,623 3,197,977 $ 1.96 $ 6,268,258 - 0.6801 - 18.35
Last Trade Time Type Quantity Stock Price Currency
16:14:17 formt 356 $ 1.89 USD


Draw Mode:

Spero Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 66.28M 35.07M 29.76M $ 18.26M $ - -2.91 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -1.59M 2.70%

more financials information »

Spero Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SPRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.922.281.822.044,106,388-0.03-1.56%
1 Month1.243.180.812.1016,511,7210.6552.42%
3 Months0.82953.180.68011.838,190,3081.06127.85%
6 Months7.117.870.68011.834,211,731-5.22-73.42%
1 Year17.3218.350.68012.162,179,452-15.43-89.09%
3 Years10.4323.6390.68013.96845,837-8.54-81.88%
5 Years13.2523.6390.68014.37548,740-11.36-85.74%

Spero Therapeutics Description

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Your Recent History
Spero Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221007 20:29:17